However, long-term anti-androgen receptor (AR) therapy was shown to alter the prostate cell lineage, leading to epithelial-mesenchymal transition (EMT), treatment resistance, and neuroendocrine (NE) differentiation (NED) of prostate cancer cells [2]. The gene discussed is AR; the disease is prostate carcinoma.